FDA approves Advisor HD Grid Mapping Catheter, Sensor Enabled for ablation to treat cardiac arrhythmias- Abbott.

Abbott announced FDA clearance of the Advisor HD Grid Mapping Catheter, Sensor Enabled. Advisor HD Grid employs a new design that allows physicians to see things differently, capturing and analyzing data in a novel manner to create highly detailed maps of the heart that better differentiate healthy from unhealthy tissue. The new mapping catheter builds upon Abbott's innovative products designed to improve how physicians perform cardiac ablation procedures, including the EnSite Precision Cardiac Mapping System and a broad range of mapping and treatment catheters. For people battling complex arrhythmias, physicians may use cardiac ablation therapy to create lesions on the heart to disrupt the electrical pathways causing the erratic heart beats. To ensure the best outcomes for their patients, physicians first need to identify which areas of the heart contain those pathways. Mapping catheters are critical to providing this insight -- delivering an inside view of the heart so physicians can navigate cardiac anatomy to deliver more precise ablation therapy.

The Advisor HD Grid Mapping Catheter, Sensor Enabled received CE Mark approval in December 2017 .

Comment: For patients battling complex arrhythmias, physicians may use cardiac ablation therapy to create tiny scars or lesions on the heart to stop erratic electrical signals. Yet to ensure the best outcomes for their patients, physicians first need to identify which areas of the heart are responsible for those signals. Mapping catheters are critical to providing this insight..